Download App

Log in to access Online Inquiry
Company Overview More
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company’s product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
CEO: Chacko M.B.A., M.D., Jacob M.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

ORIC Oric Pharmaceuticals

3.480-0.200-5.43%
Trading Session 05/19 13:56 ET
High
3.690
Open
3.600
Turnover
460.93K
Low
3.400
Pre Close
3.680
Volume
131.59K
Market Cap
137.38M
P/E(TTM)
Loss
52wk High
26.700
Shares
39.48M
P/E(Static)
Loss
52wk Low
2.620
Float Cap
88.47M
Bid/Ask %
77.78%
Historical High
40.810
Shs Float
25.42M
Volume Ratio
0.30
Historical Low
2.620
Dividend TTM
--
Div Yield TTM
--
P/B
0.54
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.52%
Amplitude
7.88%
Avg Price
3.502
Lot Size
1
Float Cap
88.47M
Bid/Ask %
77.78%
Historical High
40.810
Shs Float
25.42M
Volume Ratio
0.30
Historical Low
2.620
Dividend TTM
--
P/B
0.54
Dividend LFY
--
Turnover Ratio
0.52%
Amplitude
7.88%
Avg Price
3.502
Lot Size
1
Price Forecast

No Data

News

Comment